Akthelia Pharmaceuticals featured in Icelandic newspaper Viðskiptablaðið
Akthelia Pharmaceuticals Awarded RANNIS Grant to Accelerate Development of Gastrimod® (AKT-011) for Chemotherapy-Induced FN
Akthelia Pharmaceuticals presents new translational mucosal barrier injury efficacy data at NLSD 2024
Akthelia receives European Commission Seal of Excellence
Meet Akthelia Pharmaceuticals at the LSX World Congress 2024
Dr Sonja Srdanović joins Akthelia Pharma as R&D Program Manager for Inflammation and Infection
Meet Akthelia Pharmaceuticals at Nordic Life Science Days, 2023
Dr Helga Einarsdóttir joins Akthelia Pharma as R&D Program Manager for Wound Therapeutics
Akthelia Pharmaceuticals and the University of Iceland Secure a €6M EU Horizon Grant
Akthelia Pharmaceuticals is selected to present at the Science4Peace Summit in Stockholm
Akthelia Pharmaceuticals Participates in the LSX Leaders Nordic Congress 2022
Akthelia Pharmaceuticals Announces Second Close of Follow-Up Pre-Seed Equity Round
Akthelia Pharmaceuticals Announces Close of Follow-Up Pre-Seed Equity Round
Dr Steingrímur Stefánsson joins Akthelia Pharma in the role of Senior Scientist
Akthelia Pharma is awarded a RANNÍS grant for wound healing
Akthelia Pharma Announces Close of a Pre-Seed Equity Round
Akthelia Pharma is awarded a RANNÍS grant towards a POC of its innate immunity approach
Akthelia will attend the 2019 ANTIMICROBIAL PEPTIDES GORDON RESEARCH CONFERENCE